Mallinckrodt PLC (NYSE:MNK) – Investment analysts at Jefferies Financial Group reduced their FY2021 earnings per share estimates for shares of Mallinckrodt in a report released on Tuesday, November 6th. Jefferies Financial Group analyst A. Petrone now expects that the company will post earnings per share of $8.04 for the year, down from their prior estimate of $9.00.

A number of other equities analysts have also weighed in on the company. Berenberg Bank set a $23.00 target price on Mallinckrodt and gave the stock a “sell” rating in a research report on Wednesday. Wells Fargo & Co set a $27.00 target price on Mallinckrodt and gave the stock a “hold” rating in a research report on Tuesday, November 6th. Mizuho reaffirmed a “hold” rating and set a $27.00 target price on shares of Mallinckrodt in a research report on Tuesday, November 6th. Zacks Investment Research lowered Mallinckrodt from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. Finally, Goldman Sachs Group lowered Mallinckrodt from a “neutral” rating to a “sell” rating and upped their target price for the stock from $27.00 to $28.00 in a research report on Tuesday, September 11th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company. Mallinckrodt presently has a consensus rating of “Hold” and a consensus price target of $32.53.

Shares of NYSE:MNK opened at $30.89 on Friday. The company has a current ratio of 2.21, a quick ratio of 2.06 and a debt-to-equity ratio of 0.93. Mallinckrodt has a twelve month low of $11.65 and a twelve month high of $36.65. The company has a market cap of $2.60 billion, a PE ratio of 4.33, a PEG ratio of 0.41 and a beta of 1.71.

Mallinckrodt (NYSE:MNK) last issued its earnings results on Tuesday, November 6th. The company reported $2.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.31. Mallinckrodt had a return on equity of 9.60% and a net margin of 65.24%. The company had revenue of $640.00 million for the quarter, compared to analyst estimates of $634.38 million. During the same period in the prior year, the firm earned $1.97 earnings per share. Mallinckrodt’s revenue for the quarter was up 6.6% on a year-over-year basis.

A number of institutional investors have recently made changes to their positions in MNK. Advisors Preferred LLC grew its holdings in Mallinckrodt by 493.9% during the second quarter. Advisors Preferred LLC now owns 10,512 shares of the company’s stock worth $196,000 after buying an additional 8,742 shares in the last quarter. Balasa Dinverno & Foltz LLC bought a new position in Mallinckrodt in the 2nd quarter valued at $200,000. Janus Henderson Group PLC bought a new position in Mallinckrodt in the 2nd quarter valued at $237,000. Crossmark Global Holdings Inc. bought a new position in Mallinckrodt in the 3rd quarter valued at $247,000. Finally, Bronfman E.L. Rothschild L.P. grew its stake in Mallinckrodt by 46.7% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 15,238 shares of the company’s stock valued at $284,000 after purchasing an additional 4,853 shares during the period.

About Mallinckrodt

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Read More: Fundamental Analysis and Choosing Stocks

Earnings History and Estimates for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.